MSB

10.4%

$1.49 mesoblast limited

Deadline for Novartis, page-151

First 151 Last

Share
Profile

Follow
Pledge

7,198 Posts.

1326

25/03/21

22:40

Post #: 52050708
Share

“MSB is in a far better position than we were when this deal was sighed.”

Originally posted by Bazsa: ↑

"Negotiating with other big Pharma companies is stifled by this position also. Word gets out that MSB is looking to negotiate outside of Novartis and it will be hello $1 a share."

If word got out that we are negotiating with others our SP would sky rocket. Plenty of room for a better deal and MSB is in a far better position than we were when this deal was sighed. The Novartis deal as good as it sounded has already been discounted substantially as the COVD trial failed to impress. To add value to our SP MSC component we must wait for the NIH to release the results. This has huge revaluation potential as it also has implications for GVHD.

Consider the various components as a % of the current SP
CLBP is by far the strongest in my opinion , 50 % of the current SP could be attributed by market for this indication alone. I can not see any down side risk in the medium term. Upside will be modest as further development is announced.

CHF must also have a significant value being contributed to the SP. It would be better than half CLBP , 30%. like wise I see no down side short term however news of partnership and development would see a much larger SP gain potentially pushing its % component up equal to CLBP.

That leaves just 20% for the entire MSC portfolio, at peak SP last year this would have been close to 60%.
Yes we have immediate down side , very bad results from the ARDS trial that results in Novartis walking should only result in a long term decrease in % of SP of 10% or at todays price 23 cents.

Now consider the upside, COVID has lost interest in the market however I don't think it unreasonable to see the SP MSC component climb back up to more historical levels say 50% $ 3.80 . This is only considering the reinstatement of the current deal with Novartis. As we all know the implications of the ARDS results go far beyond the Novartis partnership.

The first sight of GVHD approval or any other modest income and we will be back over $5

Good luck all.

Expand

Pre Novartis deal MSB had a FDA approval chance. Post Novartis deal and MSB has no FDA approval chance. I am talking imminently.

BS is popular. I’ll give it that.

MSB Price at posting: $2.33 Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BUX

Buxton projects new graphite province discovery at WA Narryer play

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

There are more pages in this discussion • 279 more messages in this thread...

First 151 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.49		Change 0.140(10.4%)		Mkt cap ! $1.701B

Open	High	Low	Value	Volume
$1.37	$1.54	$1.37	$23.10M	15.82M

Buyers (Bids)

No.	Vol.	Price($)
3	24758	$1.49

Sellers (Offers)

Price($)	Vol.	No.
$1.49	73626	3

View Market Depth

No.	Vol.	Price($)
3	24758	1.485
5	59100	1.480
4	60253	1.475
3	35489	1.470
1	34513	1.465

Price($)	Vol.	No.
1.490	73626	3
1.505	29500	2
1.510	41232	6
1.515	123153	3
1.520	81763	5

Last trade - 16.10pm 04/10/2024 (20 minute delay)

MSB (ASX) Chart

Deadline for Novartis, page-151

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Deadline for Novartis, page-151

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News